Full Press Release Details
BEDFORD, Mass., June 12, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, announced it will present the following presentations at the upcoming 2023 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, which will be held June 24-27, 2023 in Chicago, Illinois.
PYLARIFY AI™ (aPROMISE) is the only deep learning enabled FDA-cleared medical device software to offer standardized PSMA PET reporting with PYLARIFY AI on PSMA PET/CT images, including those achieved using PYLARIFY® (piflufolastat F18) PET/CT.1 Standardized PSMA PET reporting provides consistent and precise disease burden quantification in support of patient management and tracking over time.2,3,4
“We're thrilled to present compelling data on the real-world application of AI-enabled PSMA PET imaging at SNMMI,” said Etienne Montagut, Chief Business Officer, Lantheus. “The presentations by Dr. Angellica Gordon from UCLA and Dr. Hong Song from Stanford reflect a significant milestone in our relentless pursuit of advancing prostate cancer management through cutting-edge technology and innovation. By harnessing our deep learning algorithm and extensive datasets, we are committed to sustaining our efforts to improve guidance for prostate cancer patient diagnosis and treatment.”
Presentation details are as follows:
Date & Time: Sunday, June 25, 2023, 11:00 am – 12:30 pm CT
Session Title: Physics, Instrumentation & Data Sciences
Title: Use of aPROMISE as an artificial intelligence software to automate and standardize quantitative heterogeneity of PSMA and FDG PET/CT in patients with mCRPC prior to PSMA radioligand therapy: a proof-of-concept study
Presenter: Angellica Gordon, MD, PGY-3 Nuclear Medicine Resident, UCLA
Date & Time: Monday, June 26, 2023, 11:15 am – 12:45 pm CT
Session Title: Oncology: Clinical Therapy & Diagnosis (includes Phase 2, Phase 3, post approval studies)
Title: Total and Anatomically Contextualized Quantitative 18F-DCFPyL PET at biochemical recurrence predicts subsequent biochemical progression free survival in prostate cancer patients
Presenter: Hong Song, MD, Assistant Professor of Radiology (Nuclear Medicine), Stanford
With more than 65 years of experience in delivering life-changing science, Lantheus is committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease. Lantheus is headquartered in Massachusetts and has offices in New Jersey, Canada and Sweden. For more information, visit www.lantheus.com.
Safe Harbor for Forward-Looking and Cautionary Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by their use of terms such as “can,” “introduce,” “potential” and other similar terms. Such forward-looking statements are based upon current plans, estimates and expectations that are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements include (i) our ability to successfully launch PYLARIFY AI as a commercial product; (ii) the market receptivity to PYLARIFY AI as a new digital application for quantitative assessment of PSMA PET/CT images in prostate cancer; (iii) the intellectual property protection of PYLARIFY AI; (iv) interruptions or performance problems associated with our digital application, including a service outage; (v) a network or data security incident that allows unauthorized access to our network or data or our customers’ data; and (vi) the risks and uncertainties discussed in our filings with the Securities and Exchange Commission (including those described in the Risk Factors section in our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q).
Vice President, Investor Relations
Senior Director, Corporate Communications